Last updated August 24, 2026
Key finding
All efsitora fixed-doses resulted in robust HbA1c lowering.
This phase 3 trial compared insulin efsitora alfa with insulin glargine in insulin-naive adults with type 2 diabetes, finding that both treatments effectively reduced HbA1c levels.
Quick read
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Long-Term (1–5 y)
Risk of bias
High Risk
Save research, organize studies, and quickly find important evidence again.
Plain-language summary
A plain-language read of the study’s main message and where it applies.
Study focus
This phase 3 trial compared insulin efsitora alfa with insulin glargine in insulin-naive adults with type 2 diabetes, finding that both treatments effectively reduced HbA1c levels.
The findings from this study are significant as they provide evidence for the effectiveness of efsitora in managing blood sugar levels in insulin-naive adults with type 2 diabetes. With both treatments showing similar efficacy and low hypoglycemia rates, clinicians can consider these options for patients who need insulin therapy.
Effectiveness data for some outcomes were unclear. Limited generalizability due to specific population characteristics. Potential unmeasured confounders affecting results.
Published in
Publication details and source links for this paper.
Lisa C, Julio R, Neda R, et al. Efsitora versus insulin glargine in insulin-naive adults with type 2 diabetes: a phase 3 trial. Diabetes, Obesity & Metabolism. 2026;28(7):6217-6224. doi:10.1111/dom.70814
Efsitora fixed-doses resulted in robust HbA1c lowering.
Insulin glargine demonstrated noninferior HbA1c reduction versus efsitora.
Estimated rates of combined Level 2 and 3 hypoglycemia were < 0.5 events/year.
Evidence network
Understand where this research contributes within the broader evidence network.
This study contributes evidence to Efsitora, Glargine U100 and Fasting Plasma Glucose (FPG), HbA1c, Incidence of hypoglycaemia.
This study contributes evidence to
Primary intervention
Efsitora
Primary outcomes
Evidence topics
Primary intervention
Primary outcomes
Intervention and outcome relationships this study adds to the evidence network.
Editorial context
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
3
Related topics
5
Evidence pairs
1489
Related studies
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Save studies and evidence pages, organize your personal Evidence Tracker, and keep the research you care about in one place.
Primary evidence
Evidence topic
matched_outcome
Related evidence
Evidence topic
Save evidence
Core evidence
The primary outcomes reported in this study.
Efsitora → Fasting Plasma Glucose (FPG)
Efsitora → Fasting Plasma Glucose (FPG)
Efsitora → Incidence of hypoglycaemia
Efsitora → Incidence of hypoglycaemia
Glargine U100 → Fasting Plasma Glucose (FPG)
Glargine U100 → Fasting Plasma Glucose (FPG)
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on Glargine U100 and HbA1c, Efsitora and HbA1c.
This study contributes to the evidence on the following intervention-outcome relationships.
Medications
Medications
Curated evidence collections and hubs this study is part of.
All studies on Glargine U100
Contributes to Glargine U100 evidence base.
All studies measuring HbA1c
Measures HbA1c as a key outcome.
All studies on Efsitora
Contributes to Efsitora evidence base.
Latest published studies
Published within the last 2 years.
Jump to pre-filtered views in Evidence Explorer.
3 results
2 results
3 results
2 results
3 results
Generated from the study's connected evidence using Evidence Intelligence™.
Glargine U100 may lower HbA1c.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
HbA1c
EvidenceScore™ Strong | EvidenceScore™ 78.5 | weak positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Efsitora appears to lower HbA1c.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
HbA1c
EvidenceScore™ Moderate | EvidenceScore™ 69.0 | strong positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Glargine U100 may improve fasting plasma glucose (FPG).
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
Fasting Plasma Glucose (FPG)
EvidenceScore™ Moderate | EvidenceScore™ 69.0 | moderate positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Efsitora appears to improve fasting plasma glucose (FPG).
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Fasting Plasma Glucose (FPG)
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Next steps
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Follow the topics this study contributes to.
Open broader Evidence Explorer views for this relationship.
Read related research summaries.
Focused on evidence, not advertising.
Your data is always protected.
New studies added every day.
